Online Platforms for Alzheimer's Disease Information Delivery
(eSMARTER Trial)
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment eHealth Platform, Videoconference Telehealth Platform for Alzheimer's Disease?
Research shows that eHealth platforms, like the Digital Alzheimer Center, can improve the quality of dementia care by providing disease information and connecting patients and caregivers with health professionals. Videoconferencing has been found to save time and enhance communication among healthcare providers, which is beneficial for managing complex cases in Alzheimer's care.12345
Is it safe to use online platforms for delivering Alzheimer's disease information?
How does the Online Platforms for Alzheimer's Disease Information Delivery treatment differ from other treatments for Alzheimer's?
This treatment is unique because it uses online platforms like eHealth and videoconference telehealth to provide information and support for Alzheimer's patients and their caregivers. Unlike traditional treatments, it focuses on improving knowledge, communication, and care coordination through digital means, which can save time and enhance multidisciplinary exchanges.123511
What is the purpose of this trial?
This randomized non-inferiority study will evaluate self-directed scalable electronic health platform (eHealth) methods for communicating Alzheimer's gene and biomarker results compared to videoconference telehealth disclosure with healthcare providers, as well as characterize the impacts of learning this information on the participant.
Research Team
Jessica Langbaum, PhD
Principal Investigator
Banner Alzheimer's Institute
Eligibility Criteria
This trial is for individuals who can follow the study's procedures, are fluent in English, willing to have their blood drawn for future testing, and have internet access with a device. They must understand the consent form content to participate.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-disclosure Education
Participants use eHealth platforms (ADWebPortal or ADChatbot) for pre-disclosure education
Disclosure
Participants receive Alzheimer's gene and biomarker results via eHealth platform or telehealth videoconference
Follow-up
Participants are monitored for psychological and cognitive impacts post-disclosure
Treatment Details
Interventions
- eHealth Platform
- Videoconference Telehealth Platform
Find a Clinic Near You
Who Is Running the Clinical Trial?
Banner Health
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
University of Pennsylvania
Collaborator